GlassScriptPhysician profile
Brian J Matherne
NPI 1437118890
$7,230.88
in general payments reported to CMS, 2019-2025
45 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $682 · 2021: $934 · 2022: $926 · 2023: $1,461 · 2024: $1,412 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,051.83 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $944.99 | 2021-2025 | |
| Lilly USA, LLC | $775.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $768.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $630.03 | 2019-2025 | Farxiga, Fasenra, Breztri |
| Novo Nordisk INC | $402.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $257.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.05 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $226.47 | 2019-2025 | Belsomra, Dificid, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $176.63 | 2021-2025 | |
| Exact Sciences Corporation | $135.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $134.06 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $122.03 | 2020-2024 | Xarelto |
| Amgen INC. | $121.34 | 2019-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.65 | 2019-2024 | Xifaxan, Trulance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Matherne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.